The pharmaceutical giant's stock has tumbled over the past year and a half, but it could be poised to storm back.

Novo Nordisk A/S secures FDA nod for oral Wegovy, expanding obesity treatment options. Click for how oral GLP-1 therapies ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Major stock indexes ended higher for a fourth straight session Tuesday, with the S&P 500 setting a fresh closing record, ...

The race to treat obesity with powerful new medicines has become one of the defining stories in global healthcare, and Novo ...

Amgen Inc. raises 2025 revenue guidance on strong Repatha and Imdelltra sales and dividend hike. Click for this AMGN update.

Novo Nordisk (NVO) is a global healthcare company and a prominent player in the diabetes market with a full portfolio of glucagon-like peptide 1 (GLP-1) receptor agonists, modern insulins and human ...